Tag: Atricure

AtriCure Announces Launch of the cryoICE® cryoSPHERE™ Probe

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced that it has launched the cryoICE® cryoSPHERE™ probe in the United States. The cryoSPHERE probe is the first device in the cryoICE family solely dedicated to blocking pain by […]

AtriCure to Announce Fourth Quarter and Full Year 2018 Financial Results

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2018 financial results on Thursday, February 28, 2019. AtriCure will host a conference call at 4:30 p.m. Eastern […]

AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2018

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the fourth quarter and full year 2018 and provided 2019 financial guidance. Preliminary, unaudited revenue for fourth quarter 2018 is expected to be […]

AtriCure to Present at the Piper Jaffray 30th Annual Healthcare Conference

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Piper Jaffray 30thAnnual Healthcare Conference in New York City on Wednesday, November 28. Management is scheduled to present at 8:00 a.m. Eastern […]

AtriCure Reports Third Quarter 2018 Financial Results

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2018 financial results. “We are pleased with our third quarter performance and building track record of strong, consistent, revenue growth,” said Mike Carrel, President and Chief […]

AtriCure to Participate in Upcoming Investor Conferences

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will be participating in upcoming investor conferences. AtriCure is scheduled to present at the Stifel 2018 Healthcare Conference in New York City on Wednesday, […]

AtriCure Announces Proposed Public Offering of Common Stock

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced it has commenced an underwritten public offering of 2.5 million shares of its common stock pursuant to its existing shelf registration statement. In connection with this offering, […]

AtriCure Announces Completion of Patient Enrollment in the CONVERGE IDE Clinical Trial

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has completed enrollment of the full cohort of 153 patients in the CONVERGE IDE clinical trial. The CONVERGE IDE trial is a landmark prospective, randomized trial […]

AtriCure to Present at the Morgan Stanley Global Healthcare Conference

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt Hotel in New York on Friday, September 14, 2018. Management is scheduled to present […]